Emerging oligonucleotide therapeutics for rare neuromuscular diseases
Research and drug development concerning rare diseases are at the cutting edge of scientific technology. To date, over 7,000 rare diseases have been identified. Despite their individual rarity, 1 in 10 individuals worldwide is affected by a rare condition. For the majority of these diseases, there i...
Auteurs principaux: | Aoki, Y, Wood, MJA |
---|---|
Format: | Journal article |
Langue: | English |
Publié: |
IOS Press
2021
|
Documents similaires
-
Oligonucleotide-based therapies for neuromuscular disease
par: Douglas, A, et autres
Publié: (2015) -
Peptide-conjugate antisense based splice-correction for Duchenne muscular dystrophy and other neuromuscular diseases
par: Tsoumpra, MK, et autres
Publié: (2019) -
Advances in oligonucleotide drug delivery
par: Roberts, TC, et autres
Publié: (2020) -
Recent advances in antisense oligonucleotide therapy in genetic neuromuscular diseases
par: Ashok Verma
Publié: (2018-01-01) -
Cell-penetrating peptide conjugates of steric blocking oligonucleotides as therapeutics for neuromuscular diseases from a historical perspective to current prospects of treatment
par: Gait, M, et autres
Publié: (2018)